Clinical trial · no report yet · Phase 3
LUNAR-2
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT06216301 ↗
- Recruiting
- NovoCure GmbH
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 5 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- NovoTTF-200T; Pembrolizumab; Platinum based chemotherapy
- Arms
- Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy · Experimental
- Arm 2: Pembrolizumab and Platinum-based Chemotherapy · Active comparator
- Enrollment
- 734 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Progression Free Survival (PFS)
- Sponsor
- NovoCure GmbH
- Start
- Jul 31, 2024
- Primary completion
- Oct 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06216301 · updated Oct 6, 2026